Real-World Analysis Reveals Psychiatric Risks and Dosing Challenges with GLP-1 Agonists

GLP-1 receptor agonists (GLP-1 RAs) like semaglutide and tirzepatide have revolutionized the treatment of obesity and type 2 diabetes due to their significant efficacy in weight loss and glycemic control. While their benefits are well-established in clinical trials, there's a growing need to understand their safety profile and practical administration challenges in diverse, real-world patient populations. This study specifically addresses the knowledge gap regarding the prevalence and nature of psychiatric adverse events and administration difficulties associated with GLP-1 RAs for weight loss in a real-world setting.

The analysis revealed that psychiatric adverse events were reported in approximately 5.8% of all GLP-1 RA users, highlighting a notable safety signal. Among these, anxiety was the most frequently reported psychiatric event, occurring in 3.2% of cases, followed closely by depression at 2.1%. While rare, reports of suicidal ideation were observed in 0.05% of patients using GLP-1 RAs, representing a statistically significant 2.3-fold increase compared to patients using other non-GLP-1 RA weight loss medications (p<0.01). Administration challenges, such as injection site reactions, nausea, and difficulties with adherence to once-weekly or daily dosing protocols, were reported in 12.5% of the total patient population. The most critical finding was a statistically significant 2.3-fold increase in reports of suicidal ideation among GLP-1 RA users compared to other weight loss interventions (p<0.01), underscoring a potential serious psychiatric risk.